Items Tagged ‘Bavencio Avelumab’

May 15th, 2017

Avelumab Immunotherapy Approved for Bladder Cancer


Bavencio (Avelumab), a programmed cell death ligand–1 (PD L1) inhibitor, has been approved for treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Discuss this article with other patients and caregivers- CancerConnect. About Urothelial Cancer Bladder […]

View full entry

Tags: Bavencio Avelumab, Bladder Cancer, News, precison medicine